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Abstract
Background: The aim of this study was to compare the properties and feasibility of the glucose analog,
2-18F-fluoro-2-deoxy-D-glucose (18F-FDG), three short 18F-labeled carboxylic acids, 18F-fluoroacetate (18F-FAC),
2-18F-fluoropropionic acid (18F-FPA) and 4-(18F)fluorobenzoic acid (18F-FBA), for differentiating tumors from
inflammation.
Methods: Biodistributions of 18F-FAC, 18F-FPA and 18F-FBA were determined on normal Kunming mice, and
positron emission tomography (PET) imaging with these tracers were performed on the separate tumor-bearing mice
model and inflammation mice model in comparison with 18F-FDG.
Results: Biodistribution results showed that 18F-FAC and 18F-FPA had similar biodistribution profiles and the slow
radioactivity clearance from most tissues excluding the in vivo defluorination of 18F-FAC, and 18F-FBA demonstrated
a lower uptake and fast clearance in most tissues. PET imaging with 18F-FDG, 18F-FAC and 18F-FPA revealed the high
uptake in both tumor and inflammatory lesions. The ratios of tumor-to-inflammation were 1.63 ± 0.28 for
18F-FDG, 1.20 ± 0.38 for 18F-FAC, and 1.41 ± 0.33 for 18F-FPA at 60 min postinjection, respectively. While clear
tumor images with high contrast between tumor and inflammation lesion were observed in 18F-FBA/PET with
the highest ratio of tumor-to-inflammation (1.98 ± 0.15).
Conclusions: Our data demonstrated 18F-FBA is a promising PET probe to distinguish tumor from inflammation. But
the further modification of 18F-FBA structure is required to improve its pharmacokinetics.
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Background
Positron emission tomography (PET) has been used for
assessing neoplasms for several decades. 2-18F-fluoro-2-
deoxy-D-glucose (18F-FDG) is the most widely used PET
probe to detect cancer based on elevated glucose metabol-
ism in the malignant tissue (Warburg effect), as a result of
increased expression of cellular membrane glucose trans-
porters (mainly transporter 1) and enhanced hexokinase II
enzymatic activity in tumor cells [1, 2]. There are some
limitations of 18F-FDG in tumor imaging, such as the
uptake in activated inflammatory cells causing the false-
positive results [3, 4], the low specificity for justified
detection of some tumors [5], and the high accumula-
tion in the brain limiting the detection of brain me-
tastases [6, 7]. Given the limitations of 18F-FDG PET
imaging, the novel imaging agents with greater tumor
specificity are required.
Some radiolabeled short carboxylic acids have been
investigated for tumor imaging. Radiolabeled acetate
(such as 11C-acetate) has been used for many years as
a probe for measuring myocardial oxidative metabol-
ism and tumor imaging [8–10], but the short half-life
of 11C (20.4 min) limited its widespread applications.
18F-fluoroacetate (18F-FAC) has been developed as a
mimic of 11C-acetate for imaging prostate cancer with
higher tumor-to-background ratios than 11C-acetate
[11]. 2-18F-fluoropropionic acid (18F-FPA) was another
important mimic of 11C-acetate, which could delineate
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both androgen-dependent and androgen-independent
prostate xenografts with high tumor-to-background
ratios [12]. There was less report about 18F-FAC and
18F-FPA in inflammation imaging [13]. 4-18F-fluoro-
benzoic acid (18F-FBA) was initially developed as a
fluorine-18-labeled reagent for coupling with small
peptides from solid phase synthesis [14]. To the best
of our knowledge, no studies about 18F-FBA as a
probe in PET imaging have been reported. Therefore,
the main purpose of this study was to investigate the
biodistribution and PET imaging of these three 18F-la-
beled short carboxylic acids (18F-FAC, 18F-FPA and
18F-FBA) and to evaluate their feasibility for differen-
tiating between tumor and inflammation in model
mice in comparison with 18F-FDG.
Methods
Radiopharmaceuticals
Automated synthesis of 18F-FDG was performed on an
automatic synthesizer (IBA, Belgium). 18F-FAC was pro-
duced by radiofluorination of benzyl bromoacetate and
followed by deprotection using on-column basic hydroly-
sis according to the method described by Tang et al. [15].
18F-FPA was prepared according to our previously re-
ported method including nucleophilic fluorination of the
precursor methyl-2-bromopropionate and deprotection
using on-column basic hydrolysis protocols [16]. 18F-FBA
was produced via two-step one-pot procedure consisting
of radiofluorination of ethyl-4-(trimethylammoniumtri-
flate) benzoate and basic hydrolysis described by Marik
and Sutcliffe [17].
Animal models
The animal experiments were approved by the Com-
mittee on Animal and Human Research at the First
Affiliated Hospital, Sun Yat-Sen University. And a com-
pleted ARRIVE guidelines checklist for animal experi-
ments is included in Supplementary Material. Female
Kunming mice (20–25 g body weight) were obtained
from Laboratory Animal Center of Sun Yat-Sen Univer-
sity. Tumor-bearing mice model and inflammation
mice model were prepared in different mice as two sep-
arate models. S-180 fibrosarcoma cells were cultured in
α-minimum essential medium (MEM, containing 10 %
fetal bovine serum, 100 U/mL penicillin and 100 μg/mL
streptomycin) at 37 °C in a humidified atmosphere with
5 % CO2. Thirty mice were subcutaneously injected
with S-180 fibrosarcoma cells (6 × 106 cells per mouse)
into the right shoulder blade. The mass of the tumors
grew to 8–10 mm within two weeks for the experiments.
Sterile inflammation was induced by injecting tur-
pentine oil, which would give rise to chronic inflam-
mation with fibroblasts, vascular proliferation and
macrophage infiltration [18]. Turpentine oil (0.2 mL
per mouse) were intramuscularly injected into the
right thigh muscle of mice (n = 30). Initial assessment
of lesions was determined by visual examination and
palpation, and lesions were allowed to grow for 3 days
for the experiments.
Biodistributions of 18F-FAC, 18F-FPA and 18F-FBA in
normal mice
For the biodistribution study, the healthy Kunming mice
were intravenously injected with 3.7 MBq of 18F-FAC, 18F-
FPA and 18F-FBA. Following the injection, animals were
sacrificed at 5 min, 30 min, 60 min and 90 min (n = 4 each
point). Blood was collected from retro-orbital bleeding,
and the other normal tissues of interest, including the
heart, brain, liver, kidney, pancreas, intestine, stomach,
lung, muscle and bone in normal mice, were rapidly
dissected and weighed. The radioactivity was counted
with an auto-gamma counter. All measurements were
background-subtracted and decay-corrected to the time
of injection, then averaged together. Tissue radioactiv-
ity was expressed as percentage of injected dose per
gram of tissue (% ID/g).
PET imaging with 18F-FAC, 18F-FPA, 18F-FBA and 18F-FDG
PET images were obtained using an Advanced Scanner
(GEMINI GXL-16, PHILIPS, Netherlands) in three-di-
mensional acquisition mode. The experimental animals
were deeply anesthetized by intraperitoneal injection
of 5 % chloral hydrate (10 mL/kg) before imaging
and remained anesthetized through the study. PET
scanning was performed on the 3 days after turpen-
tine oil injection and 10 days after tumor implantation.
Ten-minute static PET/CT scans were performed at
30 min, 60 min, 90 min and 120 min after intraven-
ous (i.v.) administration of 3.7 MBq of 18F-labeled
radiopharmaceuticals described above. PET images
were reconstructed from the Line of Response (LOR)
RAMLA algorithm with low-dose CT images for at-
tenuation correction and localization of the lesion
site, resulting in three-dimensional images consisting
of 128 × 128 × 90 voxels of 2.0 × 2.0 × 2.0 mm3. The
regions of interest were placed on each tumor, in-
flammatory lesion and the region of left thigh muscle.
After PET imaging, the animals were sacrificed, some
interested tissues (blood, tumors, inflammation region
of the right thigh muscle and normal muscle) were
excised and weighted, and the radioactivities of these
tissues were measured with the gamma counter. The
selectivity index (SI) of radiotracers was the tumor-
to-inflammation ratio corrected for the background
activity of blood or muscle according to the following
formula:
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SI ¼ Tumoruptake‐BloodorMuscleuptake½ 
Inflammationuptake‐BloodorMuscleuptake½ 
Histopathology
The excised tumors, inflammation region of the thigh
muscle and normal thigh muscle were fixed in formalin
and embedded in paraffin. Five micron sections of each
tissue were stained with hematoxylin and eosin, and ex-
amined for tumor and inflammatory region.
Statistical analysis
All reported values were expressed as mean ± standard
error of the mean. Differences among the various groups
(18F-FDG, 18F-FAC, 18F-FPA and 18F-FBA tissues uptake
after PET imaging) were tested for statistical significance
using the Student’s t test (or Wilcoxon signed rank test
when the data dose not follow a normal distribution.),
respectively. And the differences were considered signifi-
cant at the 95 % confidence level (p < 0.05).
Results
Radiosynthesis
Starting from benzyl bromoacetate and methyl-2-bro-
mopropionate, the automated synthesis of 18F-FAC and
18F-FPA were performed in approximately 36 min. And
the uncorrected radiochemical yields were 55 ± 5 % and
46 ± 7 % (n = 5) at end of synthesis for 18F-FAC and 18F-
FPA, respectively. Using one-pot procedure and purifica-
tion by SEP-PAK cartridges, the radiochemical yield of
18F-FBA was 32 ± 3 % at end of synthesis (n = 5, decay un-
corrected) within 50 min. The specific activity of 18F-FAC,
18F-FPA and 18F-FBA were >37 GBq/μmol with over than
95 % radiochemical purity.
Biodistributions of 18F-FAC, 18F-FPA and 18F-FBA in
normal mice
Biodistributions of 18F-FAC, 18F-FPA and 18F-FBA at dif-
ferent time phases in normal mice are shown in Fig. 1.
For 18F-FAC (Fig. 1a), the elimination of radioactivity
from blood was relatively slow within 60 min (6.64 ±
1.40 % ID/g at 5 min vs. 6.92 ± 2.27 % ID/g at 60 min
postinjection, p > 0.05). In addition, the radioactivity
accumulation in liver, lung, heart, muscle and pancreas
showed a similar profile of radioactivity clearance as
that in blood within 60 min. But a higher radioactivity
uptake in bone was found at 60 min postinjection
(6.68 ± 0.43 %ID/g). For 18F-FPA (Fig. 1b), the uptake
of this tracer in most investigated organs remained
constant throughout the experiment time of the study,
and the distribution profile of 18F-FPA in most tissues
was similar to that of 18F-FAC. However, the lower up-
take of 18F-FPA in bone was observed with the con-
stant radioactivity accumulation over the whole time of
study (3.91 ± 0.57 % ID/g at 5 min vs. 3.02 ± 0.07
%ID/g at 90 min, p > 0.05). For 18F-FBA, the most tis-
sue uptakes at 60 min postinjection were lower than
those of 18F-FAC and 18F-FPA (Fig. 1c), and the
radioactivity clearance of 18F-FBA from most tissues
was very fast within the experiment time, especially
for blood and kidneys (Blood: 3.63 ± 1.77 % ID/g at
5 min vs. 0.14 ± 0.08 % ID/g at 60 min, p < 0.05; Kidneys:
21.69 ± 11.3 % ID/g at 5 min vs. 0.34 ± 0.18 % ID/g at
60 min, p < 0.05).
PET imaging with 18F-FDG, 18F-FAC, 18F-FPA and 18F-FBA
in model mice
PET images of 18F-FDG, 18F-FAC, 18F-FPA and 18F-FBA
obtained in tumor-bearing mice and inflammation mice
are shown in Fig. 2. In the PET-CT images of tumor-
bearing mice, the radioactivity of 18F-FDG, 18F-FAC and
18F-FPA is clearly localized in S-180 tumor on the right
shoulder blade. In the PET-CT images of inflammatory
mice, the highest uptake of 18F-FDG in the inflammatory
tissue and the moderate uptake of 18F-FAC and 18F-FPA
were observed. For 18F-FBA, the uptake in tumor re-
vealed that 18F-FBA accumulation was significantly
lower than those of 18F-FAC and 18F-FPA. However,
there is no significant 18F-FBA uptake in inflammation
lesions.
After PET imaging, the accumulations of radioactivity
in blood, brain, liver, muscle, tumor and inflammatory
lesions derived from the excised tissues, which were ac-
quired at 60 min postinjection of tracers, are shown in
Table 1.
The comparative orders of tumor-to-muscle (Tu/Mu)
ratios were 18F-FDG (6.30 ± 0.69) > 18F-FBA (2.76 ±
0.25) > 18F-FPA (1.80 ± 0.19) > 18F-FAC (1.70 ± 0.16). And
the highest inflammation-to-muscle (Inf/Mu) ratio was
3.87 ± 0.61 for 18F-FDG, and other ratios of Inf/Mu ba-
sically were close for 18F-FAC (1.42 ± 0.13), 18F-FBA
(1.40 ± 0.13) and 18F-FPA (1.38 ± 0.13). For 18F-FAC, the
high radioactivity accumulation in muscle made it diffi-
cult to differentiate between tumor and inflammation
(Tu/Mu vs. Inf/Mu: 1.70 ± 0.16 vs. 1.42 ± 0.13, p > 0.05).
Although the 18F-FPA had the similar tumor-to-
inflammation ratio to that of 18F-FAC, the selectivity in-
dices (SI) (Tu/Inf ratios corrected with muscle and
blood uptake) of 18F-FPA (3.52 ± 0.13 and 8.00 ± 1.37)
were significantly higher than those of 18F-FAC (1.74 ±
0.16 and 1.59 ± 0.12). For 18F-FBA, significant lower
radioactivity accumulations were observed in tumor and
inflammatory lesion, but the Tumor-to-inflammation
(Tu/Inf ) ratio of 18F-FBA was the highest (1.98 ± 0.15)
among these experimental PET tracers due to the lower
inflammation uptake. Being corrected with the back-
ground uptake of muscle, 18F-FBA has a supreme select-
ivity index (SI) (Muscle corrected, 3.72 ± 0.06) due to its
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Fig. 1 The biodistributions of 18F-FAC (a), 18F-FPA (b) and 18F-FBA (c) in normal Kunming mice
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comparatively low radioactivity accumulation in the in-
flammatory lesion. Our results indicated that 18F-FBA
was specifically retained in S180 fibrosarcoma lesions.
Histopathologic findings of tumors and inflammation
Histological examination revealed malignant mesen-
chymal tumor in a specimen of the excised S-180
tumors. S-180 tumor cells with pleomorphic, hyperchro-
matic nuclei were arranged in tumor mass and many
mitoses were found (Fig. 3a). As shown in Fig. 3b, histo-
logical examination demonstrated inflammatory reaction
in a specimen of the turpentine oil-injected muscle, and
massive infiltration of neutrophils was seen in and be-
tween muscle fibers.
Fig. 2 PET images of S180 fibrosarcoma-bearing mice model (the up two rows) and sterile inflammation mice model (the below two rows)
with 18F-FDG, 18F-FAC, 18F-FPA and 18F-FBA at 60 min postinjection. Four short white lines indicate the location of tumor or inflammatory
lesion areas, respectively
Table 1 Accumulation comparison of 18F-FAC, 18F-FPA, 18F-FBA and 18F-FDG (3.7 MBq in saline) in model mice (n = 3)
18F-FDG 18F-FAC 18F-FPA 18F-FBA
Blooda 0.72 ± 0.18 3.36 ± 1.66 4.35 ± 1.09 0.05 ± 0.01
Musclea 1.06 ± 0.47 3.73 ± 0.53 3.87 ± 0.42 0.22 ± 0.02
Tumora 6.67 ± 1.13 6.12 ± 1.76 6.51 ± 1.28 0.63 ± 0.10
Inflammationa 4.11 ± 1.96 5.10 ± 0.33 4.62 ± 0.33 0.31 ± 0.04
Tumor-to-Bloodb 1.68 ± 0.26 1.82 ± 0.45 1.50 ± 0.36 12.60 ± 2.12
Inflammation-to-Blood 1.03 ± 0.14 1.52 ± 0.21 1.06 ± 0.26 6.20 ± 1.06
Tumor-to-Muscle 6.30 ± 0.69 1.70 ± 0.16 1.80 ± 0.19 2.76 ± 0.25
Inflammation-to-Muscle 3.87 ± 0.61 1.42 ± 0.13 1.38 ± 0.13 1.40 ± 0.13
Tumor-to-Inflammation 1.63 ± 0.28 1.20 ± 0.38 1.41 ± 0.33 1.98 ± 0.15*
SI (Blood)c 1.76 ± 0.23 1.59 ± 0.12 8.00 ± 1.37* 2.23 ± 0.34
SI (Muscle)d 1.84 ± 0.17 1.74 ± 0.16 3.52 ± 0.13* 3.72 ± 0.06*
aValues were presented as % ID/g (mean ± SD)
bDefined as (Tumor uptake)/(Blood uptake)
cDefined as (Tumor uptake − Blood uptake)/ (Inflammation uptake − Blood uptake), that is, Tu/Inf ratio corrected for blood background activity
dTu/Inf ratio corrected for Muscle background activity
*p < 0.05, vs. the ratios for 18F-FDG
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Discussion
In the view of the positive accumulation of 18F-FDG in
both tumor and inflammatory cells, the false-positive
findings are always accompanied with uptake of 18F-
FDG in the inflammatory lesions, such as the abscess or
granulation tissues surrounding the abscess. Hence,
many radiotracers have been developed to use in differ-
entiating tumor from inflammatory lesions [19, 20].
Radiolabeled short carboxylic acids would be an add-
itional tool in characterizing the tumor by measuring
the lipid metabolism. Tumor uptake of radiolabeled
acetate not only reflects the expression of cytosolic
acetyl-coenzyme A (CoA) synthetase [8], but also the
fatty acid synthase [21]. The fatty acid synthase is over-
expressed in various cancers and could catalyze the de
novo synthesis of fatty acids from acetyl-CoA [22, 23].
In this study, the feasibility of differentiation between
tumor and inflammation in vivo with positron emitter-
labeled short chain alkyl and aryl carboxylic acids was
investigated and compared with 18F-FDG.
In the biodistribution studies, the two short alkyl car-
boxylic acids (18F-FAC and 18F-FPA) showed the similar
characteristic of pharmacokinetics. The most tissues per-
formed both higher radioactivity accumulation and
slower clearance for 18F-FAC and 18F-FPA than those of
18F-FBA. The main reason for the slow clearance of 18F-
FAC from those tissues could be attributed to the lack of
oxidative metabolism in tissues and the slow transform-
ation of 18F-FAC to 2-18F-fluoroacetyl-CoA [24], as well
as the fluorocitric acid (in vivo) conversed from 2-18F-
fluoroacetyl-CoA could inhibit the aconitase causing the
inhibition of the tricarboxylic acid cycle [24, 25]. Several
studies have reported the utilization of propionate as a
favoured energy substrate by heart and tumor cells [25–29].
And the metabolism of propionic acid begins with its con-
version to propionyl-CoA catalyzed by mitochondrial
propionyl-CoA synthetases [30, 31], as the first common
step in the metabolism of fatty acids. Therefore, 18F-FPA
could have a similar metabolic mechanism to 18F-FAC.
Unlike the significant defluorination of 18F-FAC (Fig. 1a),
18F-FPA within 90 min postinjection appeared to show no
evidence of defluorination (Fig. 1b), which was consistent
with previous studies [12]. In contrast, 18F-FBA showed a
faster radioactivity clearance from most tissues within
60 min postinjection. Meanwhile, most tissues had a lower
radioactivity uptake of 18F-FBA after 5 min postinjection
than those of 18F-FAC and 18F-FPA, so that 18F-FBA per-
formed the low bioavailability and the primarily excretion
from kidney, which would result in a massively radioactivity
accumulation in bladder (Fig. 2).
In this study, the S-180 fibrosarcoma is a malignant
mesenchymal tumor derived from fibrous connective tis-
sue and characterized by the presence of immature prolif-
erating fibroblasts or undifferentiated anaplastic spindle
cells in a storiform pattern. And the animal model of
inflammation in the current study is chronic inflammation
characterized by fibroblast proliferation and neovasculari-
zation with mononuclear cell infiltration (macrophages,
lymphocytes and plasma cells) [18]. Therefore, we investi-
gated the fibroblasts cells uptake for different probes in
these models both with fibroblast proliferation. Our previ-
ous reports had shown that 18F-FDG/PET exhibited high
accumulations both in S-180 fibrosarcoma tumor and
inflammation lesions [31, 32]. The 18F-FDG uptake in
tumor and inflammatory were 6.30-fold and 3.87-fold
higher than that in healthy muscle, respectively (Table 1).
All these results proved that 18F-FDG could not effect-
ively achieve the differentiation between tumor and
inflammation [33]. Both 18F-FAC and 18F-FPA also suc-
cessfully delineated tumor xenografts and inflammation
lesions in model mice. For 18F-FPA, the ratio of tumor-
to-inflammation was lower than that of 18F-FDG
(Table 1), but the higher selectivity indices of tumor-to-
inflammation (muscle or blood corrected ratios of
tumor-to-inflammation, 3.52 ± 0.13 or 8.00 ± 1.37) were
observed. The significant uptake of 18F-FAC and 18F-
FPA in the inflammatory lesions might be attributed to
the high expression of the acetyl- or propionyl-CoA
synthetases and fatty acid synthnase in these tissues
[34–36]. In addition, the higher uptake of 18F-FAC and
Fig. 3 Microscopic histological examination of a specimen excised from tumor and inflammation in mice. A specimen of mice tumor (a), 10 days
after inoculation of S-180 cells and the mice inflammatory muscle (b), 72 h after injection of turpentine oil (all specimens were stained by
hematoxylin and eosin and magnified by × 400)
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18F-FPA were observed in the lower part of the gut,
which was a result of the re-absorption of small carbox-
ylic acids occurrence [37].
For 18F-FBA, the biodistribution studies demonstrated
that 18F-FBA had an advantage of rapid clearance in the
most tissues. The differences of biodistribution between
18F-FBA and 18F-FAC (or 18F-FPA) could be attributed
to the different metabolic pathway, and 18F-FBA was
converted into p-18F-fluorohippuric acid derivatives via a
glycine-conjugation pathway in the liver and eliminated
through the kidneys [38–40]. Meanwhile, 18F-FBA PET
imaging showed the clear contrast between tumor and
inflammation lesion with the highest ratios of tumor-to-
inflammation as 1.98 ± 0.15. Although both the fast
clearance and low uptake in the most tissues rendered
the high selectivity index of 18F-FBA (Muscle or Blood
corrected ratios of tumor-to-inflammation, 3.72 ± 0.06 or
2.23 ± 0.34), the low radioactivity accumulation in tumor
and inflammation would be adverse for the delimitation
of the interested tissues in PET imaging. Due to the low
uptake of 18F-FBA in tumor, some new strategies should
be attempted to modify the profiles of 18F-FBA to im-
prove its pharmacokinetics. Recently, it was reported
that the new benzoic acid derivatives could be conju-
gated with amino acids to provide new potential PET
tracers for tumor detection [41]. However, all these
works needed to be further studied.
Conclusion
In this study, the ex vivo biodistribution and in vivo PET
imaging results demonstrate that 18F-FBA seems to be a
potential PET tracer to detect tumor and to differentiate
tumor from inflammation in comparison with 18F-FDG
and 18F-FAC (or 18F-FPA). And the structure modifica-
tion of 18F-FBA would be performed to improve the pro-
files of biodistribution in the further studies.
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